138 related articles for article (PubMed ID: 31198461)
21. Early Diagnosis of Hearing Loss in Patients Under Methadone Maintenance Treatment.
Bayat A; Saki N; Mirmomeni G; Yadollahpour A
Front Neurol; 2019; 10():749. PubMed ID: 31379709
[No Abstract] [Full Text] [Related]
22. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
23. Frequency of sensory neural hearing loss in major Beta-thalassemias in southern iran.
Faramarzi A; Karimi M; Heydari ST; Shishegar M; Kaviani M
Iran J Pediatr; 2010 Sep; 20(3):308-12. PubMed ID: 23056722
[TBL] [Abstract][Full Text] [Related]
24. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
25. Sensorineural hearing loss in children with thalassemia major in Northern Greece.
Kontzoglou G; Koussi A; Tsatra J; Noussios G; Vital V; Sagarakis G; Athanassiou M
Int J Pediatr Otorhinolaryngol; 1996 May; 35(3):223-30. PubMed ID: 8762595
[TBL] [Abstract][Full Text] [Related]
26. Auditory cortex hypoperfusion: a metabolic hallmark in Beta Thalassemia.
Manara R; Ponticorvo S; Perrotta S; Barillari MR; Costa G; Brotto D; Di Concilio R; Ciancio A; De Michele E; Carafa PA; Canna A; Russo AG; Troisi D; Caiazza M; Ammendola F; Roberti D; Santoro C; Picariello S; Valentino MS; Inserra E; Carfora R; Cirillo M; Raimo S; Santangelo G; di Salle F; Esposito F; Tartaglione I
Orphanet J Rare Dis; 2021 Aug; 16(1):349. PubMed ID: 34353346
[TBL] [Abstract][Full Text] [Related]
27. High-frequency hearing influences lower-frequency distortion-product otoacoustic emissions.
Arnold DJ; Lonsbury-Martin BL; Martin GK
Arch Otolaryngol Head Neck Surg; 1999 Feb; 125(2):215-22. PubMed ID: 10037289
[TBL] [Abstract][Full Text] [Related]
28. Hearing evaluation with distortion-product otoacoustic emissions in young patients undergoing haemodialysis.
Stavroulaki P; Nikolopoulos TP; Psarommatis I; Apostolopoulos N
Clin Otolaryngol Allied Sci; 2001 Jun; 26(3):235-42. PubMed ID: 11437849
[TBL] [Abstract][Full Text] [Related]
29. [Study on distortion product otoacoustic emissions and expanded high frequency audiometry in noise exposure workers].
Han J; Li F; Zhao C; Zhang Z; Ni D
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Jan; 17(1):16-9. PubMed ID: 12725180
[TBL] [Abstract][Full Text] [Related]
30. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine.
Hassan MA; Tolba OA
Electron Physician; 2016 May; 8(5):2425-31. PubMed ID: 27382454
[TBL] [Abstract][Full Text] [Related]
31. The effects of aging on distortion-product otoacoustic emissions in adults with normal hearing.
Uchida Y; Ando F; Shimokata H; Sugiura S; Ueda H; Nakashima T
Ear Hear; 2008 Apr; 29(2):176-84. PubMed ID: 18595184
[TBL] [Abstract][Full Text] [Related]
32. PCB exposure and cochlear function at age 6 years.
Palkovičová Murínová Ľ; Moleti A; Sisto R; Wimmerová S; Jusko TA; Tihányi J; Jurečková D; Kováč J; Koštiaková V; Drobná B; Trnovec T
Environ Res; 2016 Nov; 151():428-435. PubMed ID: 27552711
[TBL] [Abstract][Full Text] [Related]
33. Measuring of distortion product otoacoustic emissions using multiple tone pairs.
Kastanioudakis I; Ziavra N; Anastasopoulos D; Skevas A
Eur Arch Otorhinolaryngol; 2003 Aug; 260(7):395-400. PubMed ID: 12937915
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of sensorineural hearing loss with neural networks versus logistic regression modeling of distortion product otoacoustic emissions.
Ziavra N; Kastanioudakis I; Trikalinos TA; Skevas A; Ioannidis JP
Audiol Neurootol; 2004; 9(2):81-7. PubMed ID: 14981356
[TBL] [Abstract][Full Text] [Related]
35. The Incidence of Ototoxicity in Patients Using Iron Chelators.
Derin S; Azık FM; Topal Y; Topal H; Karakuş V; Çetinkaya PU; Şahan M; Azık TE; Kocabaş CN
J Int Adv Otol; 2017 Apr; 13(1):136-139. PubMed ID: 27879229
[TBL] [Abstract][Full Text] [Related]
36. Hearing screening with portable screening pure-tone audiometer and distortion-product otoacoustic emissions.
Wang YF; Wang SS; Tai CC; Lin LC; Shiao AS
Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jun; 65(6):285-92. PubMed ID: 12201570
[TBL] [Abstract][Full Text] [Related]
37. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine.
Styles LA; Vichinsky EP
J Pediatr Hematol Oncol; 1996 Feb; 18(1):42-5. PubMed ID: 8556369
[TBL] [Abstract][Full Text] [Related]
38. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
39. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
40. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
Chiodo AA; Alberti PW; Sher GD; Francombe WH; Tyler B
J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
